98%
921
2 minutes
20
Background: Holistic multimodal interventions have not been established for cancer cachexia. The beliefs and perceptions of health care professionals (HCPs) based on their experiences influence the interventions.
Objectives: HCPs' knowledge, perceptions, and practices in cancer cachexia management were evaluated.
Design/setting/subjects/measurements: A nationwide questionnaire survey was conducted that focused on the perspectives of HCPs on interventions in 451 designated cancer hospitals across Japan. Descriptive statistics were applied.
Results: Among 2255 participants, 1320 responded (58.5%), and 1188 in 258 institutes were included in the analysis. The current international definition of cancer cachexia is not commonly known and recent clinical practice guidelines have not been widely adopted. More than 50% of participants considered ≥5% weight loss in six months and ECOG PS (Eastern Cooperative Oncology Group Performance Status) 2-4 to be cancer cachexia, whereas 50% answered that there was no relationship between life expectancy and cancer cachexia. Participants tended to consider it important to initiate nutritional and exercise interventions before cancer cachexia becomes apparent. The majority of participants recognized the importance of holistic multimodal interventions, particularly for the management of physical and psychological symptoms; however, only 20% reported that they educated patients and families. Furthermore, 33% of participants considered themselves to have provided patients and families with sufficient nutritional and exercise interventions and evidence-based information.
Conclusion: The results reveal that HCPs are not regularly providing education and emotional support to patients and families suffering from cancer cachexia. The results also show the need for education for HCPs to enhance implementation of holistic multimodal interventions for cancer cachexia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811833 | PMC |
http://dx.doi.org/10.1089/pmr.2022.0045 | DOI Listing |
Support Care Cancer
September 2025
Department of Palliative Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Purpose: There are no methods for assessing the need for multimodal care in cancer cachexia. We examined nine components in evaluating needs among advanced cancer patients.
Methods: This was a self-administered survey.
Food Funct
September 2025
College of Veterinary Medicine, Shanxi Agricultural University, Taiyuan, Shanxi 030801, China.
Eggs play an important role in skeletal muscle development, but their active components are unknown. The aim of this study was to investigate the effect of yolk extract-derived vitellogenin 2 on dexamethasone (DEX)- and cancer cachexia (CC)-induced skeletal muscle atrophy. We used iTRAQ to detect the changes in protein expression between fertilized egg yolk extract (FEYE) and unfertilized egg yolk extract (UEYE).
View Article and Find Full Text PDFMol Cancer
September 2025
School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Neuron
September 2025
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA; Northwell Health, New Hyde Park, NY 11042, USA. Electronic address:
This NeuroView explores how systemic cancer signals induce behavioral changes via brain-body communication pathways, framing cachexia as an adaptive yet unsustainable interoceptive response. Recognizing patient-reported symptoms as biological signals offers new avenues for intervention and understanding brain-disease interactions.
View Article and Find Full Text PDFCancer Causes Control
September 2025
Huntsman Cancer Institute, Salt Lake City, UT, USA.
Background: Cachexia accounts for about 20% of all cancer-related deaths and it is indicative of poor prognosis and progressive functional impairment. The role of the gut microbiome in the development of cachexia in colorectal cancer (CRC) patients has not been established.
Methods: Pre-surgical stool samples from n = 103 stage I-III CRC patients in the ColoCare Study were analyzed using 16S rRNA gene sequencing (Illumina) to characterize fecal bacteria.